© 1991 by Oxford University Press
Journal of the National Cancer Institute, Vol. 83, No. 11, 757-766,
June 5, 1991
© 1991 Oxford University Press
Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines
Sponsored in pan by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under conuact NOICO-23910 with Program Resources. Inc.
Program Resources, Inc., NCI-Frederick Cancer Research and Development Center Frederick, Md.
Developmental Therapeutics Program, Division of Cancer Treatment, NCI-Frederick Cancer Research and Development Center Frederick, Md.
*Correspondence to: Anne Monks, PhD, NCl-Frederick Cancer Research and Development Center, Bldg 432, Rm 232, Frederick, MD 21701-1013
We describe here the development and implementation of a pilot-scale, in vitro, anticancer drug screen utilizing a panel of 60 human tumor cell lines organized into subpanels representing leukemia, melanoma, and cancers of the lung, colon, kidney, ovary, and central nervous system. The ultimate goal of this disease-oriented screen is to facilitate the discovery of new compounds with potential cell line-specific and/or subpanel-specific antitumor activity. In the current screening protocol, each cell line is inoculated onto microtiter plates, then preincubated for 24–28 hours. Subsequently, test agents are added in five 10-fold dilutions and the culture is incubated for an additional 48 hours. For each test agent, a dose-response profile is generated. End-point determinations of the cell viability or cell growth are performed by in situ fixation of cells, followed by staining with a protein-binding dye, sulforhodamine B (SRB). The SRB binds to the basic amino acids of cellular macromolecules; the solubilized stain is measured spectrophotometrically to determine relative cell growth or viability in treated and untreated cells. Following the pilot screening studies, a screening rate of 400 compounds per week has been consistently achieved.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Turk, M. D. Hall, B. F. Chu, J. A. Ludwig, H. M. Fales, M. M. Gottesman, and G. Szakacs Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells Cancer Res., November 1, 2009; 69(21): 8293 - 8301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huesca, L. S. Lock, A. A. Khine, S. Viau, R. Peralta, I. H. Cukier, H. Jin, R. A. Al-Qawasmeh, Y. Lee, J. Wright, et al. A novel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis Mol. Cancer Ther., September 1, 2009; 8(9): 2586 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Blair, C. A. Larson, R. Safaei, and S. B. Howell Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin Clin. Cancer Res., July 1, 2009; 15(13): 4312 - 4321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schoeberl, E. A. Pace, J. B. Fitzgerald, B. D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, R. Bukhalid, et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis Sci. Signal., June 30, 2009; 2(77): ra31 - ra31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shichiri, N. Fukai, Y. Kono, and Y. Tanaka Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers Cancer Res., June 1, 2009; 69(11): 4760 - 4768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Lucas, R. B. Edwards, G. Lozanski, D. A. West, J. D. Shin, M. A. Vargo, M. E. Davis, D. M. Rozewski, A. J. Johnson, B.-N. Su, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo Blood, May 7, 2009; 113(19): 4656 - 4666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Larson, B. G. Blair, R. Safaei, and S. B. Howell The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs Mol. Pharmacol., February 1, 2009; 75(2): 324 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. K. Mirzoeva, D. Das, L. M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N. J. Wang, R. M. Neve, Y. Guan, et al. Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition Cancer Res., January 15, 2009; 69(2): 565 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Jandial, S. Farshchi-Heydari, C. A. Larson, G. I. Elliott, W. J. Wrasidlo, and S. B. Howell Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1 Clin. Cancer Res., January 15, 2009; 15(2): 553 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Riedel, A. Porrello, E. Pontzer, E. J. Chenette, D. S. Hsu, B. Balakumaran, A. Potti, J. Nevins, and P. G. Febbo A genomic approach to identify molecular pathways associated with chemotherapy resistance Mol. Cancer Ther., October 1, 2008; 7(10): 3141 - 3149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dewaele, B. Wasag, J. Cools, R. Sciot, H. Prenen, P. Vandenberghe, A. Wozniak, P. Schoffski, P. Marynen, and M. Debiec-Rychter Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation Clin. Cancer Res., September 15, 2008; 14(18): 5749 - 5758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tian, T. H. Landowski, O. W. Stephens, S. Yaccoby, B. Barlogie, and J. D. Shaughnessy Jr. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma Mol. Cancer Ther., March 1, 2008; 7(3): 500 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Leoni, B. Bailey, J. Reifert, H. H. Bendall, R. W. Zeller, J. Corbeil, G. Elliott, and C. C. Niemeyer Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents Clin. Cancer Res., January 1, 2008; 14(1): 309 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Reddy, K. D. Burroughs, L. M. Hales, S. Ganesh, B. H. Jones, N. Idamakanti, C. Hay, S. S. Li, K. L. Skele, A.-J. Vasko, et al. Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers J Natl Cancer Inst, November 7, 2007; 99(21): 1623 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab Cancer Res., November 1, 2007; 67(21): 10556 - 10563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Rao, K. Agama, S. Holbeck, and Y. Pommier Batracylin (NSC 320846), a Dual Inhibitor of DNA Topoisomerases I and II Induces Histone {gamma}-H2AX as a Biomarker of DNA Damage Cancer Res., October 15, 2007; 67(20): 9971 - 9979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh, et al. YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts Cancer Res., September 1, 2007; 67(17): 8014 - 8021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Bromberg, H. M. Kluger, A. Delaunay, S. Abbas, K. A. DiVito, S. Krajewski, and Z. Ronai Increased Expression of the E3 Ubiquitin Ligase RNF5 Is Associated with Decreased Survival in Breast Cancer Cancer Res., September 1, 2007; 67(17): 8172 - 8179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Gills, J. LoPiccolo, J. Tsurutani, R. H. Shoemaker, C. J.M. Best, M. S. Abu-Asab, J. Borojerdi, N. A. Warfel, E. R. Gardner, M. Danish, et al. Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo Clin. Cancer Res., September 1, 2007; 13(17): 5183 - 5194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Lee, D. M. Havaleshko, H. Cho, J. N. Weinstein, E. P. Kaldjian, J. Karpovich, A. Grimshaw, and D. Theodorescu A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery PNAS, August 7, 2007; 104(32): 13086 - 13091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. T. Shankavaram, W. C. Reinhold, S. Nishizuka, S. Major, D. Morita, K. K. Chary, M. A. Reimers, U. Scherf, A. Kahn, D. Dolginow, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study Mol. Cancer Ther., March 1, 2007; 6(3): 820 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-C. Andersson, S. Stromberg, H. Backvall, C. Kampf, M. Uhlen, K. Wester, and F. Ponten Analysis of Protein Expression in Cell Microarrays: A Tool for Antibody-based Proteomics J. Histochem. Cytochem., December 1, 2006; 54(12): 1413 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. N. Ikediobi, H. Davies, G. Bignell, S. Edkins, C. Stevens, S. O'Meara, T. Santarius, T. Avis, S. Barthorpe, L. Brackenbury, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set Mol. Cancer Ther., November 1, 2006; 5(11): 2606 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Lorenzi, W. C. Reinhold, M. Rudelius, M. Gunsior, U. Shankavaram, K. J. Bussey, U. Scherf, G. S. Eichler, S. E. Martin, K. Chin, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells Mol. Cancer Ther., November 1, 2006; 5(11): 2613 - 2623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tolliday, P. A. Clemons, P. Ferraiolo, A. N. Koehler, T. A. Lewis, X. Li, S. L. Schreiber, D. S. Gerhard, and S. Eliasof Small Molecules, Big Players: the National Cancer Institute's Initiative for Chemical Genetics. Cancer Res., September 15, 2006; 66(18): 8935 - 8942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Fischer, S. Muller-Weeks, and S. J. Caradonna Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase. Cancer Res., September 1, 2006; 66(17): 8829 - 8837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Yaguchi, Y. Fukui, I. Koshimizu, H. Yoshimi, T. Matsuno, H. Gouda, S. Hirono, K. Yamazaki, and T. Yamori Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst, April 19, 2006; 98(8): 545 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Macor, D. Mezzanzanica, C. Cossetti, P. Alberti, M. Figini, S. Canevari, and F. Tedesco Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res., April 1, 2006; 66(7): 3876 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Gills, S. Holbeck, M. Hollingshead, S. M. Hewitt, A. P. Kozikowski, and P. A. Dennis Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol. Cancer Ther., March 1, 2006; 5(3): 713 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wallqvist, J. Connelly, E. A. Sausville, D. G. Covell, and A. Monks Differential Gene Expression as a Potential Classifier of 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole-Sensitive and -Insensitive Cell Lines Mol. Pharmacol., March 1, 2006; 69(3): 737 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kolonin, L. Bover, J. Sun, A. J. Zurita, K.-A. Do, J. Lahdenranta, M. Cardo-Vila, R. J. Giordano, D. E. Jaalouk, M. G. Ozawa, et al. Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries Cancer Res., January 1, 2006; 66(1): 34 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kong, E. J. Park, A. G. Stephen, M. Calvani, J. H. Cardellina, A. Monks, R. J. Fisher, R. H. Shoemaker, and G. Melillo Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity Cancer Res., October 1, 2005; 65(19): 9047 - 9055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wallqvist, R. Huang, D. G. Covell, A. V. Roschke, K. S. Gelhaus, and I. R. Kirsch Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells Mol. Cancer Ther., October 1, 2005; 4(10): 1559 - 1568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kosakowska-Cholody, W. M. Cholody, A. Monks, B. A. Woynarowska, and C. J. Michejda WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway Mol. Cancer Ther., October 1, 2005; 4(10): 1617 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Lin, R. Deveney, M. Barbara, N. N. Iscove, S. D. Nimer, C. Slape, and P. D. Aplan OLIG2 (BHLHB1), a bHLH Transcription Factor, Contributes to Leukemogenesis in Concert with LMO1 Cancer Res., August 15, 2005; 65(16): 7151 - 7158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krajewska, H. Kim, E. Shin, S. Kennedy, M. J. Duffy, Y. F. Wong, D. Marr, J. Mikolajczyk, A. Shabaik, I. Meinhold-Heerlein, et al. Tumor-Associated Alterations in Caspase-14 Expression in Epithelial Malignancies Clin. Cancer Res., August 1, 2005; 11(15): 5462 - 5471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Teraishi, S. Wu, J. Sasaki, L. Zhang, H.-B. Zhu, J. J. Davis, and B. Fang P-Glycoprotein-Independent Apoptosis Induction by a Novel Synthetic Compound, MMPT [5-[(4-Methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone] J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nakatsu, Y. Yoshida, K. Yamazaki, T. Nakamura, S. Dan, Y. Fukui, and T. Yamori Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays Mol. Cancer Ther., March 1, 2005; 4(3): 399 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, A. Braun, Z. Bauman, H. Olteanu, P. Madzelan, and R. Banerjee Expression Profiling of Homocysteine Junction Enzymes in the NCI60 Panel of Human Cancer Cell Lines Cancer Res., February 15, 2005; 65(4): 1554 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sandberg and I. Ernberg Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI) PNAS, February 8, 2005; 102(6): 2052 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gourdeau, L. Leblond, B. Hamelin, K. Dong, F. Ouellet, C. Boudreau, D. Custeau, A. Richard, M.-J. Gilbert, and J. Jolivet Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics: Implications for Clinical Development Clin. Cancer Res., November 15, 2004; 10(22): 7692 - 7702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Svingen, D. Loegering, J. Rodriquez, X. W. Meng, P. W. Mesner Jr., S. Holbeck, A. Monks, S. Krajewski, D. A. Scudiero, E. A. Sausville, et al. Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel Clin. Cancer Res., October 15, 2004; 10(20): 6807 - 6820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hartley, V. J. Spanswick, N. Brooks, P. H. Clingen, P. J. McHugh, D. Hochhauser, R. B. Pedley, L. R. Kelland, M. C. Alley, R. Schultz, et al. SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: Part 1: Cellular Pharmacology, In vitro and Initial In vivo Antitumor Activity Cancer Res., September 15, 2004; 64(18): 6693 - 6699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Dziba and K. B. Ain Imatinib Mesylate (Gleevec; STI571) Monotherapy Is Ineffective in Suppressing Human Anaplastic Thyroid Carcinoma Cell Growth in Vitro J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2127 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D Stein, T. Litman, T. Fojo, and S. E Bates A Serial Analysis of Gene Expression (SAGE) Database Analysis of Chemosensitivity: Comparing Solid Tumors with Cell Lines and Comparing Solid Tumors from Different Tissue Origins Cancer Res., April 15, 2004; 64(8): 2805 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gunnarsdottir and A. A. Elfarra CYTOTOXICITY OF THE NOVEL GLUTATHIONE-ACTIVATED THIOPURINE PRODRUGS CIS-AVTP [CIS-6-(2-ACETYLVINYLTHIO)PURINE] AND TRANS-AVTG [TRANS-6-(2-ACETYLVINYLTHIO)GUANINE] RESULTS FROM THE NATIONAL CANCER INSTITUTE'S ANTICANCER DRUG SCREEN Drug Metab. Dispos., March 1, 2004; 32(3): 321 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zoli, L. Ricotti, A. Tesei, P. Ulivi, A. G. Campani, F. Fabbri, R. Gunelli, G. L. Frassineti, and D. Amadori Schedule-Dependent Cytotoxic Interaction between Epidoxorubicin and Gemcitabine in Human Bladder Cancer Cells in Vitro Clin. Cancer Res., February 15, 2004; 10(4): 1500 - 1507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Jansen, C. E. Camalier, C. Stark, and N. H. Colburn Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity Mol. Cancer Ther., February 1, 2004; 3(2): 103 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Whittaker, M. I. Walton, M. D. Garrett, and P. Workman The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway Cancer Res., January 1, 2004; 64(1): 262 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Roschke, G. Tonon, K. S. Gehlhaus, N. McTyre, K. J. Bussey, S. Lababidi, D. A. Scudiero, J. N. Weinstein, and I. R. Kirsch Karyotypic Complexity of the NCI-60 Drug-Screening Panel Cancer Res., December 15, 2003; 63(24): 8634 - 8647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Mariadason, D. Arango, Q. Shi, A. J. Wilson, G. A. Corner, C. Nicholas, M. J. Aranes, M. Lesser, E. L. Schwartz, and L. H. Augenlicht Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin Cancer Res., December 15, 2003; 63(24): 8791 - 8812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Hose, M. Hollingshead, E. A. Sausville, and A. Monks Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity Mol. Cancer Ther., December 1, 2003; 2(12): 1265 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nishizuka, L. Charboneau, L. Young, S. Major, W. C. Reinhold, M. Waltham, H. Kouros-Mehr, K. J. Bussey, J. K. Lee, V. Espina, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays PNAS, November 25, 2003; 100(24): 14229 - 14234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Roychoudhury, K. M. Makin, T. L. Twinem, D. T. Stanton, S. L. Nelson, and C. E. Catrenich Development and Use of a High-Throughput Bacterial DNA Gyrase Assay to Identify Mammalian Topoisomerase II Inhibitors with Whole-Cell Anticancer Activity J Biomol Screen, April 1, 2003; 8(2): 157 - 163. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Prinetti, L. Basso, V. Appierto, M. G. Villani, M. Valsecchi, N. Loberto, S. Prioni, V. Chigorno, E. Cavadini, F. Formelli, et al. Altered Sphingolipid Metabolism in N-(4-Hydroxyphenyl)- retinamide-resistant A2780 Human Ovarian Carcinoma Cells J. Biol. Chem., February 14, 2003; 278(8): 5574 - 5583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al. Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary Clin. Cancer Res., December 1, 2002; 8(12): 3646 - 3657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-D. Jiang, L. Denner, Y.-H. Ling, J.-N. Li, A. Davis, Y. Wang, Y. Li, J. Roboz, L.-G. Wang, R. Perez-Soler, et al. Double Blockade of Cell Cycle at G1-S Transition and M Phase by 3-Iodoacetamido Benzoyl Ethyl Ester, a New Type of Tubulin Ligand Cancer Res., November 1, 2002; 62(21): 6080 - 6088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Umemura, T. Mizushima, H. Katayama, Y. Kiryu, T. Yamori, and T. Andoh Inhibition of DNA Topoisomerases II and/or I by Pyrazolo[1,5-a]indole Derivatives and Their Growth Inhibitory Activities Mol. Pharmacol., October 1, 2002; 62(4): 873 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lindholm, J. Gullbo, P. Claeson, U. Goransson, S. Johansson, A. Backlund, R. Larsson, and L. Bohlin Selective Cytotoxicity Evaluation in Anticancer Drug Screening of Fractionated Plant Extracts J Biomol Screen, August 1, 2002; 7(4): 333 - 340. [Abstract] [PDF]
|
|
|
|
|
|
A. Rapisarda, B. Uranchimeg, D. A. Scudiero, M. Selby, E. A. Sausville, R. H. Shoemaker, and G. Melillo Identification of Small Molecule Inhibitors of Hypoxia-inducible Factor 1 Transcriptional Activation Pathway Cancer Res., August 1, 2002; 62(15): 4316 - 4324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Koo, M. VanBrocklin, M. J. McWilliams, S. H. Leppla, N. S. Duesbery, and G. F. Vande Woude Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase PNAS, February 20, 2002; (2002) 52707699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dan, T. Tsunoda, O. Kitahara, R. Yanagawa, H. Zembutsu, T. Katagiri, K. Yamazaki, Y. Nakamura, and T. Yamori An Integrated Database of Chemosensitivity to 55 Anticancer Drugs and Gene Expression Profiles of 39 Human Cancer Cell Lines Cancer Res., February 1, 2002; 62(4): 1139 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Balis Evolution of Anticancer Drug Discovery and the Role of Cell-Based Screening J Natl Cancer Inst, January 16, 2002; 94(2): 78 - 79. [Full Text] [PDF]
|
|
|
|
|
|
M. O. Bradley, N. L. Webb, F. H. Anthony, P. Devanesan, P. A. Witman, S. Hemamalini, M. C. Chander, S. D. Baker, L. He, S. B. Horwitz, et al. Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel Clin. Cancer Res., October 1, 2001; 7(10): 3229 - 3238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin Anticancer Effects of Thiazolidinediones Are Independent of Peroxisome Proliferator-activated Receptor {gamma} and Mediated by Inhibition of Translation Initiation Cancer Res., August 1, 2001; 61(16): 6213 - 6218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Walsh, J. A. Feulner, and A. Reilly Evidence for Functionally Significant Polymorphism of Human Glutamate Cysteine Ligase Catalytic Subunit: Association with Glutathione Levels and Drug Resistance in the National Cancer Institute Tumor Cell Line Panel Toxicol. Sci., June 1, 2001; 61(2): 218 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Vulevic,, Z. Chen, J. T. Boyd, W. Davis Jr., E. S. Walsh, M. G. Belinsky, and K. D. Tew Cloning and Characterization of Human Adenosine 5'-triphosphate-binding Cassette, Sub-family A, Transporter 2 (ABCA2) Cancer Res., April 1, 2001; 61(8): 3339 - 3347. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Grem, K. D. Danenberg, K. Behan, A. Parr, L. Young, P. V. Danenberg, D. Nguyen, J. Drake, A. Monks, and C. J. Allegra Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell Lines of the National Cancer Institute's Anticancer Drug Screen Clin. Cancer Res., April 1, 2001; 7(4): 999 - 1009. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Meinhold-Heerlein, F. Stenner-Liewen, H. Liewen, S. Kitada, M. Krajewska, S. Krajewski, J. M. Zapata, A. Monks, D. A. Scudiero, T. Bauknecht, et al. Expression and Potential Role of Fas-Associated Phosphatase-1 in Ovarian Cancer Am. J. Pathol., April 1, 2001; 158(4): 1335 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Mertins, T. G. Myers, M. Hollingshead, D. Dykes, E. Bodde, P. Tsai, C. A. Jefferis, R. Gupta, W. M. Linehan, M. Alley, et al. Screening for and Identification of Novel Agents Directed at Renal Cell Carcinoma Clin. Cancer Res., March 1, 2001; 7(3): 620 - 633. [Abstract] [Full Text]
|
|
|
|
|
|
A. R. Salomon, D. W. Voehringer, L. A. Herzenberg, and C. Khosla Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F0F1-ATPase PNAS, December 19, 2000; 97(26): 14766 - 14771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Perez-Soler, B. Kemp, Q. P. Wu, L. Mao, J. Gomez, A. Zeleniuch-Jacquotte, H. Yee, J. S. Lee, J. Jagirdar, and Y. H. Ling Response and Determinants of Sensitivity to Paclitaxel in Human Non-Small Cell Lung Cancer Tumors Heterotransplanted in Nude Mice Clin. Cancer Res., December 1, 2000; 6(12): 4932 - 4938. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Amundson, T. G. Myers, D. Scudiero, S. Kitada, J. C. Reed, and A. J. Fornace Jr. An Informatics Approach Identifying Markers of Chemosensitivity in Human Cancer Cell Lines Cancer Res., November 1, 2000; 60(21): 6101 - 6110. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Palakurthi, R. Fluckiger, H. Aktas, A. K. Changolkar, A. Shahsafaei, S. Harneit, E. Kilic, and J. A. Halperin Inhibition of Translation Initiation Mediates the Anticancer Effect of the n-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid Cancer Res., June 1, 2000; 60(11): 2919 - 2925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Newman, J. C. Rodarte, K. D. Benbatoul, S. J. Romano, C. Zhang, S. Krane, E. J. Moran, R. T. Uyeda, R. Dixon, E. S. Guns, et al. Discovery and Characterization of OC144-093, a Novel Inhibitor of P-Glycoprotein-mediated Multidrug Resistance Cancer Res., June 1, 2000; 60(11): 2964 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R.A. Mans, A. B. da Rocha, and G. Schwartsmann Anti-Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as a Rational Strategy to Acquire Candidate Anti-Cancer Compounds Oncologist, June 1, 2000; 5(3): 185 - 198. [Abstract] [Full Text]
|
|
|
|
|
|
C. P. Webb, C. D. Hose, S. Koochekpour, M. Jeffers, M. Oskarsson, E. Sausville, A. Monks, and G. F. Vande Woude The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network Cancer Res., January 1, 2000; 60(2): 342 - 349. [Abstract] [Full Text]
|
|
|
|
|
|
H.-M. Koo, M. J. McWilliams, W. G. Alvord, and G. F. Vande Woude Ras Oncogene-Induced Sensitization to 1-{{beta}}-D-Arabinofuranosylcytosine Cancer Res., December 1, 1999; 59(24): 6057 - 6062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kubo, K. Nakagawa, R. K. Varma, N. K. Conrad, J. Q. Cheng, W.-C. Lee, J. R. Testa, B. E. Johnson, F. J. Kaye, and M. J. Kelley The p16 Status of Tumor Cell Lines Identifies Small Molecule Inhibitors Specific for Cyclin-dependent Kinase 4 Clin. Cancer Res., December 1, 1999; 5(12): 4279 - 4286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Nieves-Neira, M. I. Rivera, G. Kohlhagen, M. L. Hursey, P. Pourquier, E. A. Sausville, and Y. Pommier DNA Protein Cross-Links Produced by NSC 652287, a Novel Thiophene Derivative Active Against Human Renal Cancer Cells Mol. Pharmacol., September 1, 1999; 56(3): 478 - 484. [Abstract] [Full Text]
|
|
|
|
|
|
S. Jariyawat, T. Sekine, M. Takeda, N. Apiwattanakul, Y. Kanai, S. Sophasan, and H. Endou The Interaction and Transport of beta -Lactam Antibiotics with the Cloned Rat Renal Organic Anion Transporter 1 J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 672 - 677. [Abstract] [Full Text]
|
|
|
|
|
|
I. Naasani, H. Seimiya, T. Yamori, and T. Tsuruo FJ5002: A Potent Telomerase Inhibitor Identified by Exploiting the Disease-oriented Screening Program with COMPARE Analysis Cancer Res., August 1, 1999; 59(16): 4004 - 4011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamori, A. Matsunaga, S. Sato, K. Yamazaki, A. Komi, K. Ishizu, I. Mita, H. Edatsugi, Y. Matsuba, K. Takezawa, et al. Potent Antitumor Activity of MS-247, a Novel DNA Minor Groove Binder, Evaluated by an in Vitro and in Vivo Human Cancer Cell Line Panel Cancer Res., August 1, 1999; 59(16): 4042 - 4049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Koo, M. Gray-Goodrich, G. Kohlhagen, M. J. McWilliams, M. Jeffers, A. Vaigro-Wolff, W. G. Alvord, A. Monks, K. D. Paull, Y. Pommier, et al. The ras Oncogene-Mediated Sensitization of Human Cells to Topoisomerase II Inhibitor-Induced Apoptosis J Natl Cancer Inst, February 3, 1999; 91(3): 236 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alvarez, R. Robey, V. Sandor, K. Nishiyama, Y. Matsumoto, K. Paull, S. Bates, and T. Fojo Using the National Cancer Institute Anticancer Drug Screen to Assess the Effect of MRP Expression on Drug Sensitivity Profiles Mol. Pharmacol., November 1, 1998; 54(5): 802 - 814. [Abstract] [Full Text]
|
|
|
|
|
|
V. Fischer, A. Rodríguez-Gascón, F. Heitz, R. Tynes, C. Hauck, D. Cohen, and A. E. M. Vickers The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by Human Cytochrome P450 3A. Implications for Drug-Drug Interactions and Pharmacological Activity of the Main Metabolite Drug Metab. Dispos., August 1, 1998; 26(8): 802 - 811. [Abstract] [Full Text]
|
|
|
|
|
|
S. Dhar, J. Gullbo, K. Nilsson, P. Nygren, and R. Larsson A Nonclonogenic Cytotoxicity Assay Using Primary Cultures of Patient Tumor Cells for Anticancer Drug Screening J Biomol Screen, April 1, 1998; 3(3): 207 - 216. [Abstract] [PDF]
|
|
|
|
|
|
L. A. Mickley, J.-S. Lee, Z. Weng, Z. Zhan, M. Alvarez, W. Wilson, S. E. Bates, and T. Fojo Genetic Polymorphism in MDR-1: A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors Blood, March 1, 1998; 91(5): 1749 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Shi, T. G. Myers, Y. Fan, P. M. O'Connor, K. D. Paull, S. H. Friend, and J. N. Weinstein Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity Mol. Pharmacol., February 1, 1998; 53(2): 241 - 251. [Abstract] [Full Text]
|
|
|
|
|
|
P. Verdier-Pinard, J.-Y. Lai, H.-D. Yoo, J. Yu, B. Marquez, D. G. Nagle, M. Nambu, J. D. White, J. R. Falck, W. H. Gerwick, et al. Structure-Activity Analysis of the Interaction of Curacin A, the Potent Colchicine Site Antimitotic Agent, with Tubulin and Effects of Analogs on the Growth of MCF-7 Breast Cancer Cells Mol. Pharmacol., January 1, 1998; 53(1): 62 - 76. [Abstract] [Full Text]
|
|
|
|
|
|
S. E. Bates, W. H. Wilson, A. T. Fojo, M. Alvarez, Z. Zhan, J. Regis, R. Robey, C. Hose, A. Monks, Y. K. Kang, et al. Clinical Reversal of Multidrug Resistance Oncologist, August 1, 1996; 1(4): 269 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Weinstein, K. Kohn, M. Grever, V. Viswanadhan, L. Rubinstein, A. Monks, D. Scudiero, L Welch, A. Koutsoukos, A. Chiausa, et al. Neural computing in cancer drug development: predicting mechanism of action Science, October 16, 1992; 258(5081): 447 - 451. [Abstract] [PDF]
|
|
|
|
|
|
H.-M. Koo, M. VanBrocklin, M. J. McWilliams, S. H. Leppla, N. S. Duesbery, and G. F. V. Woude Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase PNAS, March 5, 2002; 99(5): 3052 - 3057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Butte, P. Tamayo, D. Slonim, T. R. Golub, and I. S. Kohane Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks PNAS, October 24, 2000; 97(22): 12182 - 12186. [Abstract] [Full Text] [PDF]
|
|